The NHLBI has just announced Funding Opportunity Announcements for an NHLBI Progenitor Cell Translational Consortium (U01) (RFA-HL-16-021) and for an NHLBI Progenitor Cell Translational Consortium Coordinating Center (U24) (RFA-HL-16-022).
To provide the PCBC with a mechanism to quickly award small grants to junior faculty (less than 5 years from their appointment to Assistant Professor) research associates, fellows, postdocs, and graduate students to support a well-defined specific aim. The aim should involve at least one of the following, with priority given to proposals that incorporate two:
After a heart attack, millions to billions of cardiomyocytes are lost. Because the adult mammalian heart possesses little regenerative potential, a precipitous loss of cardiac function ensues. Patients with heart failure could benefit from repopulating injured areas of the heart with functional cardiomyocytes. To date, cellular transplantation has been therapeutically unsuccessful. Direct lineage reprogramming offers a new approach to repopulate cardiomyocytes in the heart.
Dr. Charles Hong’s group at the Vanderbilt Hub has signed a licensing agreement for clinical development of novel small molecule BMP inhibitors for rare genetic disease called fibrodysplasia ossificans progressiva, muscular dystrophy and variety of cancers that are driven by aberrant BMP signaling. Earlier versions of BMP inhibitors that the Hong group developed, such as dorsomorphin and DMH1, have been widely used to direct differentiation of pluripotent stem cells toward cardiovascular, neuronal and other lineages.